In particular, the authors demonstrate that the TLR7 agonist had a superior tumor inhibitory effect in a metastatic model of lung adenocarcinoma, relative to anti-PD1 therapy or platinum-based chemotherapy [59]. This evidence concerns the gene TLR7 and neoplasm.